Recombinant hepatitis B vaccination of neonates and infants: Emerging safety data from the Vaccine Adverse Event Reporting System

Pediatric Infectious Disease Journal

Volumn 15, Issue 9, 1996, Pages 771-776

  Niu, Manette T ^a,b   Davis, David M ^a   Ellenberg, Susan ^a  

^a Center for Biologics Evaluation and Research   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

adverse events; Hepatitis B vaccine; infants; Vaccine Adverse Event Reporting System (VAERS)

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS B VACCINE; RECOMBINANT VACCINE;

AGITATION; APNEA; ARTICLE; CONVULSION; CYANOSIS; DRUG SAFETY; FEVER; HEPATITIS B; HUMAN; INFANT; MAJOR CLINICAL STUDY; MUSCLE HYPOTONIA; NEWBORN; PRIORITY JOURNAL; RASH; STUPOR; VACCINATION;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS B VACCINES; HUMANS; INFANT; INFANT, NEWBORN; INFORMATION SYSTEMS; MALE; VACCINATION; VACCINES, SYNTHETIC;

EID: 0029808247     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199609000-00007     Document Type: Article

References (44)

1. Centers for Disease Control. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1991:40(Suppl RR-13):11-3.
2. "Recombivax HB," "Engerix-B." In: Physician desk reference (PDR). Montvale, NJ: Medical Economics Data Production Co., 1995:1628-30, 2371-3.
3. Andre FE. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med 1989;87(Suppl 3A): 14S-20S.
4. FDA. Summary for basis of approval, Merck Sharp & Dohme: hepatitis B vaccine (recombinant) - Recombivax HB, No. 85-05, data on file.
5. FDA. Summary for basis of approval, SmithKline Biologicals: Engerix B, No. 87-0556, data on file.
6. FDA. Summary basis of approval, Merck Sharp & Dohme: hepatitis B vaccine (recombinant)-Recombivax HB, No. 88-0192, data on file.
7. West DJ. Clinical experience with hepatitis B vaccine. Am J Infect Control 1989;17:172-80.
8. McLean AA, Hilleman MR, McAleer WJ, Buynak EB. Summary of worldwide clinical experience with H-B-Vax (B, MSD). J Infect 1983;7(Suppl 1):95-104.
9. Greenberg DP. Pediatric experience with recombinant hepatitis B vaccines and relevant safety and immunogenicity studies. Pediatr Infect Dis J 1993;12:438-45.
10. Zajac BA, West DJ, McAller WJ, Scolnick EM. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect 1986;13(Suppl A):39-45.
11. McMahon BJ, Helminiak C, Wainwright RB, Bulkow L, Trimble BA. Frequency of adverse reactions to hepatitis B vaccine in 43 618 persons. Am J Med 1992;92:254-6.
12. Andre FE. Clinical experience with a recombinant DNA hepatitis B vaccine. Southeast Asian J Trop Med Pub Health 1988;19:501-10.
13. Andre FE, Safary A. Summary of clinical findings on Engerix-B, a genetically engineered yeast-derived hepatitis B vaccine. Postgrad Med J 1987;63(Suppl 2):169-77.
14. Andre FE. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine 1990:8(Suppl): S74-8.
15. Lee CY, Huang LM, Chang MH, et al. The protective efficacy of recombinant hepatitis B vaccine in newborn infants of hepatitis B e antigen-positive-hepatitis B surface antigen carrier mothers. Pediatr Infect Dis J 1991;10:299-303.
16. Moyes CD. Hepatitis B vaccination. NZ Med J 1994;107: 238-9.
17. Yeoh EK, Chang WK, Ip P, Chan KH, Chan E, Fung C. Efficacy and safety of recombinant hepatitis B vaccine in infants born to HBsAg-positive mothers. J Infect 1986: 13(Suppl A):15-8.
18. Gunn TR, Bosley A, Woodfield DG. The safety and immunogenicity of a recombinant hepatitis B vaccine in neonates. NZ Med J 1989;102:1-3.
19. Meheus A, Alisjahbana A, Vranckx R, et al. Immunogenicity of a recombinant DNA hepatitis B vaccine in neonates. Postgrad Med J 1987;63(Suppl 2):139-41.
20. Poovorawan Y, Sanpavat S, Pongpunlert W, Chumdermpadetsuk S, Sentrakul P, Safary A. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. JAMA 1989;261:3278-81.
21. Poovorawan Y, Sanpavat S, Pongpunlert W, et al. Comparison of a recombinant DNA hepatitis B vaccine alone or in combination with hepatitis B immune globulin for the prevention of perinatal acquisition of hepatitis B carriage. Vaccine 1990:8(Suppl):S56-9.
22. Panda SK, Ramesh R, Rao KVS, Gupta A, Zuckerman AJ, Nayak NC. Comparative evaluation of the immunogenicity of yeast-derived (recombinant) and plasma-derived hepatitis B vaccine in infants. J Med Virol 1991;35:297-302.
23. Lolekha S, Bowonkiratikachorn P, Chimabutra K. Immunogenicity and reactogenicity of a yeast-derived hepatitis B vaccine in Thai school children. J Med Assoc Thai 1989; 72(Suppl 1):98-101.
24. Barone P, Mauro L, Leonardi S, et al. Simultaneous administration of HB recombinant vaccine with diphtheria and tetanus toxoid and oral polio vaccine: a pilot study. Acta Paediatr Jpn 1991;33:455-8.
25. Tsega E, Tafesse B, Horton J, et al. Immunogenicity, reactogenicity and comparison of two doses of recombinant DNA yeast-derived hepatitis B vaccine in Ethiopian children. Trop Geogr Med 1991;43:220-7.
26. Scaravelli C, Bianchi E, Biraghi V, et al. Efficacy of minimal doses of an American hepatitis B vaccine in neonates. Clin Ther 1985;7:680-3.
27. Stevens CE, Taylor PE, Tong MJ, et al. Yeast-recombinant hepatitis B vaccine: efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B transmission. JAMA 1987;257:2612-6.
28. Greenberg DP, Vadheim CM, Marcy CM, et al. Comparative safety and immunogenicity of two recombinant hepatitis B (HBV) vaccines given to infants at 2, 4, and 6 months of age. Presented at the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, October, 1992:264.
29. Hwang LY, Lee CY, Beasley RP. Five year follow-up of HBV vaccination with plasma-derived vaccine in neonates: evaluation of immunogenicity and efficacy against perinatal transmission. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral hepatitis and liver disease. Baltimore: Williams & Wilkins, 1991:759-61.
30. Lee GCY, Hwang LY, Beasley RP, Chen SH, Lee TY. Immunogenicity of hepatitis B virus vaccine in healthy Chinese neonates. J Infect Dis 1983;148:526-9.
31. Chen RT, Rastogi SC, Mullen JR, et al. The Vaccine Adverse Event Reporting System (VAERS). Vaccine 1994;12:542-50.
32. Centers for Disease Control. Reported vaccine-preventable diseases: United States, 1993, and the childhood immunization initiative. MMWR 1994;43:57-60.
33. Centers for Disease Control. Vaccination coverage of 2-year-old children: United States. MMWR 1994;43:705-9.
34. Centers for Disease Control. Vaccination coverage levels among children aged 19-35 months: United States, April-June 1994. MMWR 1995;44:396-8.
35. Centers for Disease Control. National, state, and urban area vaccination coverage levels among children aged 19-35 months: United States, April 1994-March 1995. MMWR 1996;45:145-50.
36. Massey JT, Moore TF, Parsons VL, Tadros W. Design and estimation for the National Health Interview Survey, 1985-94: National Center for Health Statistics. Vital Health Stat 1989;2(110):6-17.
37. Shannon DC, Kelly DH. SIDS and near SIDS. N Engl J Med 1982;306:959-65, 1022-8.
38. Kraus SF, Greenland S, Bulterys M. Risk factors for sudden death syndrome in the US Collaborative Perinatal Project. J Epidemiol 1989;18:113-20.
39. Mellins RB, Haddad GG. Sudden infant death syndrome. In: Nelson WE, Behrman RE, Kliegman RM, eds. Textbook of pediatrics. Philadelphia: 1992:1759-61.
40. Di Lernia V, Lo Scocco G, Bisighini G. Erythema multiforme following hepatitis B vaccine. Pediatr Dermatol 1994;11: 363-4.
41. Feldshon SD, Sampliner RE. Reaction to hepatitis B vaccine [Letter]. Ann Intern Med 1984;100:156-7.
42. Shaw FE, Graham DJ, Guess HA, et al. Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Am J Epidemiol 1988;127:337-52.
43. Fenichel GM. Neurological complications of immunization. Ann Neurol 1982;12:119-28.
44. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barré syndrome following vaccination in the national Influenza immunization program, United States, 1976-1977. Am J Epidemiol 1979;110:105-23.